Risk factors
Alpha Cognition (ACOG) risk factors
Item 1A of every Alpha Cognition Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
76 risks, 2 new, 1 dropped, 8 reworded since the prior year. Alpha Cognition incurred significant net losses of $20.6 million in 2025 with an accumulated deficit of $97.1 million. The company relies entirely on its sole approved commercial product, ZUNVEYL.
Filed Mar 31, 2026 - FY2024 10-K risk factors
75 risks. Alpha Cognition relies heavily on the commercial success of its sole FDA-approved drug, ZUNVEYL.
Filed Mar 31, 2025